| Phase 2 trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, R Conwit, ME Cudkowicz, T Gleason, A Goodman, ... New England Journal of Medicine 379 (9), 846-855, 2018 | 268 | 2018 |
| Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? F Barkhof, HE Hulst, J Drulovic, BMJ Uitdehaag, K Matsuda, R Landin Neurology 74 (13), 1033-1040, 2010 | 164 | 2010 |
| Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression TJ Alban, D Bayik, B Otvos, A Rabljenovic, L Leng, L Jia-Shiun, G Roversi, ... Frontiers in immunology 11, 1191, 2020 | 100 | 2020 |
| Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, ME Cudkowicz, T Gleason, A Goodman, EC Klawiter, ... Contemporary clinical trials 50, 166-177, 2016 | 75 | 2016 |
| Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma LM Lewis, I Ferguson, SL House, K Aubuchon, J Schneider, K Johnson, ... Chest 145 (1), 53-59, 2014 | 58 | 2014 |
| Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) W Ha, H Sevim-Nalkiran, AM Zaman, K Matsuda, M Khasraw, AK Nowak, ... Scientific reports 9 (1), 2905, 2019 | 42 | 2019 |
| A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors AD Ricart, EA Ashton, MM Cooney, J Sarantopoulos, JM Brell, ... Cancer chemotherapy and pharmacology 68, 959-970, 2011 | 32 | 2011 |
| Treatment of progressive neurodegenerative disease with ibudilast ME Kalafer, KW Locke, K Matsuda, RE Gammans US Patent 8,138,201, 2012 | 29 | 2012 |
| Ibudilast (MN-166) in amyotrophic lateral sclerosis-an open label, safety and pharmacodynamic trial S Babu, BG Hightower, J Chan, NR Zürcher, P Kivisäkk, CEJ Tseng, ... NeuroImage: Clinical 30, 102672, 2021 | 27 | 2021 |
| Bacterial identification by 16S rRNA gene PCR-hybridization as a supplement to negative culture results K Matsuda, KK Iwaki, J Garcia-Gomez, J Hoffman, CB Inderlied, ... Journal of clinical microbiology 49 (5), 2031-2034, 2011 | 26 | 2011 |
| Ibudilast for the treatment of drug addiction and other neurological conditions. KW Johnson, K Matsuda, Y Iwaki Clinical Investigation 4 (3), 269-279, 2014 | 25 | 2014 |
| MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design B Oskarsson, N Maragakis, RS Bedlack, N Goyal, JA Meyer, A Genge, ... Neurodegenerative disease management 11 (6), 431-443, 2021 | 24 | 2021 |
| Development of a real-time quantitative PCR assay for detection of a stable genomic region of BK virus KK Iwaki, SH Qazi, J Garcia-Gomez, D Zeng, Y Matsuda, K Matsuda, ... Virology journal 7, 1-10, 2010 | 20 | 2010 |
| Adaptive design single center phosphodiesterase type 4 (PDE4) inhibitor–ibudilast (MN-166-ALS-1201) phase 1b/2a clinical trial double-blind (DB) with open label extension (OLE … BR Brooks, E Bravver, M Sanjak, V Langford, L Moore, N Smith, N Lucas, ... Neurology 88 (16 Supplement), 2017 | 10 | 2017 |
| Treatment of amyotrophic lateral sclerosis (ALS) with ibudilast ME Kalafer, KW Locke, K Matsuda, RE Gammans US Patent 9,314,452, 2016 | 10 | 2016 |
| Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation JE Schneider, LM Lewis, I Ferguson, SL House, J Liu, K Matsuda, ... Respiratory Medicine 108 (9), 1284-1291, 2014 | 10 | 2014 |
| A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical … B Brooks, E Bravver, M Sanjak, V Langford, C Lary, M Alwan, J Nemeth, ... Neurology 84 (14_supplement), I8-1B, 2015 | 9 | 2015 |
| MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an … K Matsuda, Y Iwaki Hepatology 60 (6), 1283A-1284A, 2014 | 9 | 2014 |
| Evaluation of Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist for the Treatment of Asthma via Intravenous Infusion K Matsuda, M Makhay, K Johnson, Y Iwaki Journal of Asthma 49 (10), 1071-1078, 2012 | 9 | 2012 |
| Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma SL House, K Matsuda, G O'Brien, M Makhay, Y Iwaki, I Ferguson, ... Respiratory medicine 109 (10), 1268-1273, 2015 | 8 | 2015 |
